Jade Biosciences (JBIO) announced it has entered into a licensing agreement with Paragon Therapeutics for rights to a new drug program called JADE301, targeting an undisclosed disease target. Under the deal, Jade Biosciences will pay up to $22 million in development and regulatory milestones, with $1.5 million already paid, plus potential sublicensing fees and royalties on future sales. Paragon has agreed not to develop competing antibodies for at least five years.
Who are the top institutional investors holding JADE BIOSCIENCES INC (JBIO)?
Major stakeholders currently include FMR LLC ($99.6M), Fairmount Funds Management LLC ($64.0M), Ra Capital Management, L.p. ($51.6M). Based on the latest 13F filings, there are a total of 122 tracked investment funds and institutions maintaining positions in JBIO.
What is the overall institutional sentiment toward JBIO recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $26.6M, driven by 62 managers accumulating shares while 48 reduced their exposure.
Which institutions have been selling or reducing their JBIO positions?
In the latest period, 35 funds trimmed their holdings, and 13 managers completely exited their positions. The aggregate reported sell value was $162.8M.
Are there any notable investors adding JBIO to their portfolios?
Yes, buying activity remains notable. 23 institutions opened new positions in {ticker}, and 39 existing holders added to their shares. The total reported buy value for the quarter amounted to $288.5M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter